Sanofi's latest marketcap:
As of 07/04/2025, Sanofi's market capitalization has reached $119.54 B. According to our data, Sanofi is the 156th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 119.54 B |
| Revenue (ttm) | 48.82 B |
| Net Income (ttm) | 6.81 B |
| Shares Out | 1.23 B |
| EPS (ttm) | 5.45 |
| Forward PE | 10.14 |
| Ex-Dividend Date | 05/09/2025 |
| Earnings Date | 07/24/2025 |
Sanofi's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/04/2025 | $119.54 B | 0.01% | 156 |
| 12/31/2024 | $122 B | -1.86% | 128 |
| 12/29/2023 | $124.32 B | 1.57% | 109 |
| 12/30/2022 | $122.39 B | -3.12% | 103 |
| 12/31/2021 | $126.33 B | 3.68% | 116 |
| 12/31/2020 | $121.85 B | -2.56% | 103 |
| 12/31/2019 | $125.04 B | 14.85% | 81 |
| 12/31/2018 | $108.87 B | -2.02% | 66 |
| 12/29/2017 | $111.11 B | 5.22% | 70 |
| 12/30/2016 | $105.6 B | -6.16% | 58 |
Company Profile
About Sanofi
Sanofi is a global healthcare company dedicated to researching, developing, manufacturing, and marketing therapeutic solutions. Headquartered in Paris, France, the company operates across the United States, Europe, and international markets.
Core Offerings
Sanofi provides a diverse portfolio of medicines and vaccines, including:
- Immunology & Inflammation: Treatments for autoimmune and inflammatory conditions.
- Rare Diseases: Specialized therapies for uncommon disorders.
- Neurology: Solutions for neurological conditions.
- Oncology: Innovative cancer treatments.
Vaccine Portfolio
Sanofi's vaccine offerings include:
- Pediatric vaccines for polio, pertussis, and Hib.
- Hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B.
- Influenza, booster, and meningitis vaccines.
- Travel and endemic vaccines (hepatitis A, typhoid, yellow fever, rabies).
Strategic Collaborations
Sanofi partners with leading biotech firms to advance medical innovation, including:
- Exscientia: Developing small-molecule therapies for oncology and immunology.
- ABL Bio, Inc.: Advancing treatments for alpha-synucleinopathies.
- IGM Biosciences, Inc.: Co-developing IgM antibody therapies.
- Kymera Therapeutics, Inc.: Targeting immune-inflammatory diseases with protein degrader therapies.
- Denali Therapeutics Inc.: Focused on systemic inflammatory diseases like ulcerative colitis.
Company Background
Formerly known as Sanofi-Aventis, the company rebranded as Sanofi in May 2011. Founded in 1994, Sanofi continues to drive advancements in global healthcare through cutting-edge research and strategic partnerships.
Frequently Asked Questions
-
What is Sanofi's (SNY) current market cap?As of 07/04/2025, Sanofi (including the parent company, if applicable) has an estimated market capitalization of $119.54 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Sanofi (SNY) rank globally by market cap?Sanofi global market capitalization ranking is approximately 156 as of 07/04/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.